skip to main content

Brain Tumor

How to outsmart brain cancer

Scientists at the University of Michigan Rogel Cancer Center were optimistic when they identified a small molecule that blocked a key pathway in brain tumors. But there was a problem: How to get the inhibitor through the bloodstream and into the brain to reach the tumor. In collaboration with multiple labs, the teams fabricated a nanoparticle to contain the inhibitor, and the results were even better than expected.

Researchers learn they can track pediatric glioma treatment response using spinal fluid

Treatment for glioma has long relied on MRI imaging to track tumor markers and treatment response. But findings from a team at the University of Michigan Rogel Cancer Center, led by Carl Koschmann, M.D., pediatric neuro-oncologist at University of Michigan Health C.S. Mott Children’s Hospital and researcher with the Chad Carr Pediatric Brain Tumor Center, suggest a new method could provide additional data about tumor markers before changes appear on an MRI, indicating possible strategies to help clinicians address this aggressive form of cancer.

A clinical trial for glioblastoma patients fosters innovation and hope

A new clinical trial from a team at the University of Michigan Rogel Cancer Center uses innovative basic science research methods to offer hope and a new treatment to glioblastoma patients. A collaborative team of Rogel physicians, led by Daniel Wahl, M.D., Ph.D., hopes that grounding their trial in rigorous and innovative biology from the very beginning will help this approach succeed where so many other potential glioblastoma treatments have failed.

Discovery of a gene mutation may lead to new treatments for Glioma

A mutated gene affects growth of brain tumor cells in young adults, indicating sensitivity to a new treatment strategy, a team of researchers at the Rogel Cancer Center discovered. These findings, recently published in Cell Reports, present possibilities for more effective therapies for glioma patients with this gene mutation.

Metformin shows promise against rare childhood brain tumor in laboratory studies

Metformin, a drug commonly prescribed against diabetes, holds promise against a rare type of childhood brain tumor in laboratory studies, an international team of researchers led by the Rogel Cancer Center report in Science Translational Medicine.

Targeting a mutation found in all gliomas may be the key immunotherapy success

A common mutation in gliomas sensitizes them to immunotherapy, a finding which researchers believe could have broader therapeutic implications for all glioma patients.

Combination treatment for common glioma type shows promise in mice

These encouraging results, published in the Journal of Clinical Investigation, could be the first step toward developing a treatment for this type of brain cancer.

Glioma Research in Animal Models has Promising Results

A combination approach to treating a prevalent glioma subtype -- including metabolic reprogramming, radiation, chemotherapy and immunotherapy -- led to a complete regression of tumors in 60% of study mice.

Researchers Studying Whether an Anti-Rejection Drug Is Effective Against Glioblastoma

Research led by the Rogel Cancer Center is trying a new approach: Make radiation therapy more effective for glioblastoma patients by targeting a critical metabolic pathway and disrupting its ability to repair the DNA damage caused by the radiation.

Living with Brain Cancer

Andrea Passmore learned she had a brain tumor four days before her 51st birthday. Yet she has ultimately come to see the diagnosis as a kind of gift, an opportunity to share the outpouring of support that she has received during her cancer journey.